神经胶质瘤组织中miR-203a-3p、PHOX2B表达水平与临床特征及预后的关系

doi:10.3969/j.issn.1006-5725.2024.10.009

Abstract

Abstract:

Objective To investigate the correlations microRNA-203a-3p （miR-203a-3p） and paired allographic box protein 2B （PHOX2B） expression levels in glioma tissues with clinical features and prognosis. Methods Ninety-six glioma patients admitted to our hospital from June 2017 to April 2020 were included in the study. The resected glioma tissues and corresponding paracancerous tissues from the patients were collected intraoperatively. qRT-PCR and immunohistochemistry were conducted to detect the expression of miR-203a-3p and PHOX2B mRNA in glioma tissues and paracancerous groups. Pearson's method was used to analyze the correlation between miR-203a-3p and PHOX2B mRNA. Kaplan-Meier survival curves were used to analyze the correlations of miR-203a-3p and PHOX2B mRNA with the prognosis of glioma patients. COX regression was used to analyze the risk factors affecting the prognosis of glioma patients. Results The miR-203a-3p level and positive expression rate of glioma tissues were significantly lower than that of paracancerous tissues （P < 0.05）， and the PHOX2B mRNA level and positive expression rate were significantly higher than that of paracancerous tissues （P < 0.05）. By Pearson correlation analysis， the miR-203a-3p and PHOX2B mRNA levels of glioma patients were negatively correlated （P < 0.05）. miR-203a-3p and PHOX2B were associated with KPS score， tumor tissue necrosis， and WHO grading （P < 0.05）. Kaplan-Meier curve analysis yielded the results that the survival rate of the miR-203a-3p highly expressed group was significantly higher than that of the lowly expressed group （P < 0.05）， and the survival rate of the PHOX2B mRNA highly expressed group was significantly lower than that of the lowly expressed group （P < 0.05）. COX regression analysis showed that miR-203a-3p， PHOX2B mRNA， tumor tissue necrosis， and WHO grading were the risk factors affecting the prognosis of glioma patients （P < 0.05）. Conclusion The expression level of miR-203a-3p is obviously reduced and the expression level of PHOX2B mRNA is obviously increased in glioma， both showing close correlation with clinical characteristics and prognosis.

Key words: micro RNA-203a-3p, paired-like homebox 2B, glioma, clinical characteristics, prognosis

CLC Number:

R739.41

Qi ZHANG,Jia HU,Hui LI,Jin WANG,Zhongde LI,Zhiyuan. HU. Correlations of miR⁃203a⁃3p and PHOX2B expression in glioma tissues with clinical features and prognosis[J]. The Journal of Practical Medicine, 2024, 40(10): 1382-1388.

Figures/Tables 11

Tab. 1

Tab.2

Fig.1

Tab.3

Fig.2

Fig.3

Tab.4

Fig.4

Fig.5

Tab.5

Tab.6

References 25

1	李琳，刘超，邵将，等. 肿瘤电场治疗在神经胶质瘤治疗中的研究进展［J］. 实用医学杂志， 2022， 38（22）： 2763-2767. doi:10.3969/j.issn.1006-5725.2022.22.001 doi: 10.3969/j.issn.1006-5725.2022.22.001
2	YANG K， WU Z， ZHANG H， et al. Glioma targeted therapy： insight into future of molecular approaches［J］. Mol Cancer， 2022， 21（1）：39. doi:10.1186/s12943-022-01513-z doi: 10.1186/s12943-022-01513-z
3	XU S， TANG L， LI X， et al. Immunotherapy for glioma： Current management and future application［J］. Cancer Lett， 2020， 476（1）： 1-12. doi:10.1016/j.canlet.2020.02.002 doi: 10.1016/j.canlet.2020.02.002
4	HENDERSON F， ABDULLAH K G， VERMA R， et al. Tractography and the connectome in neurosurgical treatment of gliomas： the premise， the progress， and the potential［J］. Neurosurg Focus， 2020， 48（2）： E6. doi:10.3171/2019.11.focus19785 doi: 10.3171/2019.11.focus19785
5	XIN S， HUANG K， ZHU X G. Non-coding RNAs： Regulators of gliomacell epithelial mesenc- hymal transformation ［J］. Pathol Res Pract， 2019， 215（9）：152539-152548. doi:10.1016/j.prp.2019.152539 doi: 10.1016/j.prp.2019.152539
6	李天雄，孙志鹏，尹刚，等. miR-133a-3p通过抑制氧化还原因子1抑制肝细胞恶性生物学行为［J］.中国免疫学杂志， 2020， 36（10）：1217-1223.
7	SYEDA Z ALI， LANGDEN S S S， MUNKHZUL C， et al. Regulatory Mechanism of MicroRNA Expression in Cancer［J］. Int J Mol Sci， 2020， 21（5）： 1723. doi:10.3390/ijms21051723 doi: 10.3390/ijms21051723
8	WANG Z， ZHAO Z， YANG Y， et al. MiR-99b-5p and miR-203a-3pFunction as Tumor Suppressors by Targeting IGF-IR in Gas-trie Cancer［J］.Sei Rep， 2018， 8（1）：10119-10131. doi:10.1038/s41598-018-27583-y doi: 10.1038/s41598-018-27583-y
9	CARDANI S， DI LASCIO S， BELPERIO D， et al.Desogestrel down-rgulates PHOX2B and its target genes in pro-gesterone responsiveneuroblastoma cells ［J］.Exp Cell Res， 2018， 370（2）： 671-679. doi:10.1016/j.yexcr.2018.07.032 doi: 10.1016/j.yexcr.2018.07.032
10	刘江华，臧博伦，刘炜，等. 高危神经母细胞瘤患儿骨髓中PHOX2B及GD2的表达及临床意义［J］. 中国现代医药杂志， 2022， 24（6）：1-5. doi:10.3969/j.issn.1672-9463.2022.06.001 doi: 10.3969/j.issn.1672-9463.2022.06.001
11	苏昌亮，李丽，陈小伟，等. 2016年WHO中枢神经系统肿瘤分类总结［J］. 放射学实践， 2016， 31（7）： 570-579.
12	中国脑胶质瘤协作组，中国脑胶质瘤基因组图谱计划. 中国脑胶质瘤分子诊疗指南［J］. 中华神经外科杂志， 2014， 30（5）： 435-444. doi:10.3760/cma.j.issn.1001-2346.2014.05.002 doi: 10.3760/cma.j.issn.1001-2346.2014.05.002
13	GUO X， SUI R， PIAO H. Exosomes-mediated crosstalk between glioma and immune cells in the tumor microenvironment［J］. CNS Neurosci Ther， 2023， 29（8）： 2074-2085. doi:10.1111/cns.14239 doi: 10.1111/cns.14239
14	RUFF M， KIZILBASH S， BUCKNER J. Further understanding of glioma mechanisms of pathogenesis： implications for therapeutic development［J］. Expert Rev Anticancer Ther， 2020， 20（5）：355-363. doi:10.1080/14737140.2020.1757440 doi: 10.1080/14737140.2020.1757440
15	URIBE-CARDENAS R， GIANTINI-LARSEN A M， GARTON A， et al. Innovations in the Diagnosis and Surgical Management of Low-Grade Gliomas［J］. World Neurosurg， 2022， 166（1）： 321-327. doi:10.1016/j.wneu.2022.06.070 doi: 10.1016/j.wneu.2022.06.070
16	SEYEDMIRZAEI H， SHOBEIRI P， TURGUT M， et al. VEGF levels in patients with glioma： a systematic review and meta-analysis［J］. Rev Neurosci， 2020， 32（2）： 191-202. doi:10.1515/revneuro-2020-0062 doi: 10.1515/revneuro-2020-0062
17	GAO Q， ZHOU H， WANG G， et al. A Model for Predicting Clinical Prognosis in Patients with WHO Grade 2 Glioma［J］. J Oncol， 2022， 2022（1）： 2795939. doi:10.1155/2022/2795939 doi: 10.1155/2022/2795939
18	ZHANG J， REN C， HAO S J， et al. MiRNA-491-5p inhibits cell proliferation， invasion and migration via targeting JMJD2B and serves as a potential biomarker in gastric cancer［J］. Am J Transl Res， 2018， 10（2）： 525-534.
19	MENON A， ABD-AZIZ N， KHALID K， et al. miRNA： A Promising Therapeutic Target in Cancer［J］. Int J Mol Sci， 2022， 23（19）： 11502. doi:10.3390/ijms231911502 doi: 10.3390/ijms231911502
20	LIANG J， SUN T， WANG G， et al. Clinical significance and functions of miR-203a-3p/AVL9 axis in human non-small-cell lung cancer［J］. Per Med， 2020， 17（4）： 271-282. doi:10.2217/pme-2019-0108 doi: 10.2217/pme-2019-0108
21	杨雯迪，李亚军. miR-203a-3p靶向调控VEGF-C表达对卵巢癌恶性生物学特征的影响［J］. 中国妇幼健康研究， 2022， 33（1）： 66-72. doi:10.3969/j.issn.1673-5293.2022.01.012 doi: 10.3969/j.issn.1673-5293.2022.01.012
22	AN N， ZHENG B. MiR-203a-3p Inhibits Pancreatic Cancer Cell Proliferation， EMT， and Apoptosis by Regulating SLUG［J］. Technol Cancer Res Treat， 2020， 19（1）：1533033819898729. doi:10.1177/1533033819898729 doi: 10.1177/1533033819898729
23	ALEXANDRESCU S， PAULSON V， DUBUC A， et al. PHOX2B is a reliableimmunomarker in distinguishing peripheral neuroblastie tumourfrom CNS embryonal tumours ［J］. Histopathology， 2018， 73 （3）：483-491，. doi:10.1111/his.13648 doi: 10.1111/his.13648
24	李静羽，高吉照. 同源异型盒蛋白2B在外周神经母细胞性肿瘤中表达及临床意义［J］. 临床军医杂志， 2021， 49（1）： 89-91.
25	FAN Y， CHEN P， RAZA M U， et al. Alteredexpression of phox2transcription factors in the locus coeruleus in major depressivedisorder mimicked by chronic stress and corticosterone treatment invivo and in vitro［J］. Neuroscience， 2018， 393（1）： 123-137. doi:10.1016/j.neuroscience.2018.09.038 doi: 10.1016/j.neuroscience.2018.09.038

基因	正向引物5′-3′	反向引物5′-3′
miR-203a-3p	AGGACGGCTCCTCTAACCAT	AGCGGCTCCACAAGTAAGAC
U6	CTCGCTTCGGCAGCACA	AACGCTTCACGAATTTGCGT
PHOX2B mRNA	GTGAAGACGCTGACCGGAAA	CCAGGTGAAGGACTGAACCA
GAPDH	CTCCATCCTGGCCTCGCTGT	GCTGTCACCTTCACCGTTCC

组别	例数	miR-203a-3p	PHOX2B mRNA
胶质瘤组织	96	0.58 ± 0.13	3.67 ± 0.85
癌旁组织	96	1.01 ± 0.21	1.02 ± 0.24
t值		17.058	29.397
P值		< 0.001	< 0.001

组别	例数	miR-203a-3p		PHOX2B
组别	例数	阳性	阴性	阳性	阴性
癌旁组织	96	63（65.63）	33（34.38）	31（32.29）	65（67.71）
胶质瘤组织	96	46（47.92）	50（52.08）	49（51.04）	47（48.96）
χ²值	-	6.133		6.943
P值	-	0.013		0.002

临床特征	例数	miR-203a-3p		χ ² 值	P值	PHOX2B mRNA		χ ² 值	P值
临床特征	例数	阳性（n = 46）	阴性（n = 50）	χ ² 值	P值	阳性（n = 49）	阴性（n = 47）	χ ² 值	P值
年龄				0.008	0.931			0.449	0.503
≥ 50岁	38	18（47.37）	20（52.63）			21（55.26）	17（44.74）
< 50岁	58	28（48.28）	30（51.72）			28（48.28）	30（51.72）
性别				0.032	0.858			1.475	0.225
男	51	24（47.06）	27（52.94）			29（56.86）	22（43.15）
女	45	22（48.89）	23（51.11）			20（44.44）	25（55.56）
肿瘤最大径				0.071	0.790			0.732	0.392
≥ 3.0 cm	41	19（46.34）	22（53.66）			23（56.10）	18（43.90）
< 3.0 cm	55	27（49.09）	28（50.91）			26（47.27）	29（52.73）
KPS评分				8.435	0.004			9.550	0.002
≥ 80分	52	32（61.54）	20（38.46）			19（36.54）	33（63.46）
< 80分	44	14（31.82）	30（68.18）			30（68.18）	14（31.82）
肿瘤组织坏死				9.361	0.002			7.806	0.005
有	36	10（27.78）	26（72.22）			25（69.44）	11（30.56）
无	60	36（60.00）	24（40.00）			24（40.00）	36（60.00）
WHO分级				10.101	0.001			8.337	0.004
Ⅰ?Ⅱ级	64	38（59.38）	26（40.63）			26（40.63）	38（59.38）
Ⅲ?Ⅳ级	32	8（25.00）	24（75.00）			23（71.88）	9（28.13）
肿瘤切除程度				0.021	0.885			0.252	0.616
根治切除	59	28（47.46）	31（52.54）			32（54.24）	27（45.76）
姑息切除	37	17（45.95）	20（54.05）			22（59.46）	15（40.54）

变量	赋值方式
miR-203a-3p	低表达 = 1，高表达 = 0
PHOX2B mRNA	高表达 = 1，低表达 = 0
KPS评分	≥ 80分 = 0，< 80分 = 1
肿瘤组织坏死	无 = 0，有 = 1
WHO分级	Ⅰ-Ⅱ级 = 0，Ⅲ-Ⅳ级 = 1

Correlations of miR⁃203a⁃3p and PHOX2B expression in glioma tissues with clinical features and prognosis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 11

References 25

Related Articles 15

Recommended Articles

Metrics

Comments

因素	单因素分析			多因素分析
因素	HR	95%CI	P值	HR	95%CI	P值
miR-203a-3p	6.107	3.385 ~ 11.017	< 0.001	3.454	1.353 ~ 8.815	0.010
PHOX2B mRNA	4.257	1.836 ~ 9.870	0.002	4.012	3.153 ~ 5.106	< 0.001
KPS评分	3.454	1.353 ~ 8.815	0.010	2.024	0.758 ~ 5.403	0.159
肿瘤组织坏死	5.124	2.210 ~ 11.879	< 0.001	1.771	1.201 ~ 2.611	0.004
WHO分级	2.468	1.321 ~ 4.612	0.004	3.547	1.554 ~ 8.095	0.002

[1]	Xiaomei CHEN,Anqi WANG,Jizhen YANG,Miao YU. Prognosis and immune correlation analysis of m1A/m5C/m6A/m7G regulated genes in gastric cancer [J]. The Journal of Practical Medicine, 2024, 40(9): 1230-1237.
[2]	Shihe XIAO,Gang LI,Zhonghai LIU,Zhen. LIU. Expression of ZEB2 and CCL20 in glioma tissue and their correlation with prognosis [J]. The Journal of Practical Medicine, 2024, 40(9): 1262-1267.
[3]	Futao DANG,Yingmei TANG,Haiyan FU,Huanlong LI,Jiamin XU,Xu. TAN. The efficacy of artificial （nonbiological） extracorporeal liver support system for primary biliary cholangitis and the effect of this therapy on prognosis [J]. The Journal of Practical Medicine, 2024, 40(7): 955-961.
[4]	Xiya MA,Hu JI,Zehua ZHU,Bo PAN,Qiang XIE,Xiaobo. YAO. The predictive value of ¹⁸F⁃FDG PET/CT metabolic heterogeneity parameters combined with clinical features for the prognosis of esophageal squamous cell carcinoma before definitive radiochemotherapy [J]. The Journal of Practical Medicine, 2024, 40(7): 966-971.
[5]	Yuxin CHENG,Liang LIU,Shiyu DONG,Shengchao LI,Meng ZHANG. Research advances in exosomal proteins， mRNA and non⁃coding RNA regulation of Hepatocellular Carcinoma [J]. The Journal of Practical Medicine, 2024, 40(6): 748-755.
[6]	Sibo LONG,Yan CHEN,Xintong ZHANG,Yanjun YIN,Limei YANG,Maike ZHENG,Chaohong WANG,Qing SUN,Jun YAN,Yiheng SHI,Guangli SHI,Yan ZHAO,Guirong. WANG. Serum levels of procalcitonin， interleukin⁃6 and interleukin⁃8 in patients with COVID⁃19 infection at admission and their significance in patient prognosis [J]. The Journal of Practical Medicine, 2024, 40(4): 471-475.
[7]	Zixu SONG,Guangzheng ZHU,Chenxu GUO,Jiaqi WU,Ligong ZHANG,Jun. QIAN. Expression of SLC35A2 and PFDN2 in breast cancer and its relationship with clinical observables and prognosis [J]. The Journal of Practical Medicine, 2024, 40(4): 496-502.
[8]	Yichen WANG,Yanwen YAN,Meihui SONG,Xiangjun XUE,Wenguang ZHOU,Yuquan LI,Ling QI,Guanghua LI,Xiangzong ZENG. Clinical significance of HOXB4 gene expression levels in myelodysplastic syndromes [J]. The Journal of Practical Medicine, 2024, 40(3): 321-325.
[9]	Jia CUI,Mingming ZHANG,Na WANG,Wei GAO,Fei LI. Correlation analysis of glucose and lipid metabolism indicators combined with antiphospholipid antibodies on prognosis of patients with atherosclerosis [J]. The Journal of Practical Medicine, 2024, 40(3): 326-329.
[10]	Shuang CHEN,Na YANG,Yudong HUANG,Xiangfeng KONG,Jintao LI,Yizhong TANG,Kexiong MA,Yangyang ZHANG,Yuandong ZHANG,Chengde REN. Relationship between serum miR-21 and miR-27b levels and prognosis of patients with renal clear cell carcinoma [J]. The Journal of Practical Medicine, 2024, 40(3): 343-348.
[11]	Jian ZHAO,Songjie LIU,Guanchao ZHANG,Yuhou SHEN,Fengchen LI,Bing XU. Expression of CENPF and miR⁃1⁃3p in the serum of patients with advanced gastric cancer and their correlation with prognosis [J]. The Journal of Practical Medicine, 2024, 40(3): 365-370.
[12]	Zhijie XIA,Jun LI,Qian GAO,Zhicheng LI,Zhongfang. XIA. Effect and prognosis of preauricular fistula treated by double⁃incision tunnel combined with preauricular tissue and cartilage resection [J]. The Journal of Practical Medicine, 2024, 40(22): 3179-3183.
[13]	Chengcai DAI,Zhenxing CHENG,Qianqian TU. The prognostic value of serum cystatin C combined with bedside renal ultrasound in patients with sepsis⁃induced acute kidney injury [J]. The Journal of Practical Medicine, 2024, 40(22): 3226-3231.
[14]	Kaiyang WANG,Jing TAO,Tingting WU,Jiahui YONG,Guoqing LI,Xiang XIE,Yining. YANG. Correlation of novel anthropometric indicators with long⁃term prognosis in patients with acute myocardial infarction [J]. The Journal of Practical Medicine, 2024, 40(21): 3040-3046.
[15]	Pixi WEI,Yu DENG,Cailing ZHAO,Liu XU,Min ZHANG. The expression of WDR5 in cervical cancer tissue and its relationship with clinical and pathological characteristics of patients [J]. The Journal of Practical Medicine, 2024, 40(2): 169-173.